Literature DB >> 22402937

Insulin resistance and incident peripheral artery disease in the Cardiovascular Health Study.

Kathryn A Britton1, Kenneth J Mukamal, Joachim H Ix, David S Siscovick, Anne B Newman, Ian H de Boer, Evan L Thacker, Mary L Biggs, J Michael Gaziano, Luc Djoussé.   

Abstract

Type 2 diabetes is a risk factor for peripheral artery disease (PAD), and insulin resistance is a key feature of diabetes and pre-diabetes. No longitudinal epidemiological study has examined the relation between insulin resistance and PAD. Our study analyzed the association of quartiles of the homeostatic model of insulin resistance (HOMA-IR) and the development of PAD defined by two methods. PAD was first defined as the development of an abnormal ankle-brachial index (ABI) (dichotomous outcome) after 6 years of follow-up. PAD was alternatively defined as the development of clinical PAD (time-to-event analysis). The study samples included adults over the age of 65 years who were enrolled in the Cardiovascular Health Study, had fasting measurements of insulin and glucose, had ABI measurements, and were not receiving treatment for diabetes. Multivariable models were adjusted for potential confounders, including age, sex, field center and cohort, body mass index (BMI), smoking status, alcohol use, and exercise intensity. Additional models adjusted for potential mediators, including blood pressure, lipids, kidney function, and prevalent vascular disease. In the ABI analysis (n = 2108), multivariable adjusted models demonstrated a positive relation between HOMA-IR and incident PAD (odds ratio = 1.80 comparing the 4th versus 1st quartile of HOMA-IR, 95% confidence interval [CI] 1.20-2.71). In the clinical PAD analysis (n = 4208), we found a similar relation (hazard ratio = 2.30 comparing the 4th versus 1st quartile of HOMA-IR, 95% CI 1.15-4.58). As expected, further adjustment for potential mediators led to some attenuation of effect estimates. In conclusion, insulin resistance is associated with a higher risk of PAD in older adults.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22402937      PMCID: PMC3563259          DOI: 10.1177/1358863X11436195

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  26 in total

Review 1.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II.

Authors:  Thomas F Lüscher; Mark A Creager; Joshua A Beckman; Francesco Cosentino
Journal:  Circulation       Date:  2003-09-30       Impact factor: 29.690

Review 2.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

Authors:  Mark A Creager; Thomas F Lüscher; Francesco Cosentino; Joshua A Beckman
Journal:  Circulation       Date:  2003-09-23       Impact factor: 29.690

3.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 5.  Molecular mechanisms of insulin resistance that impact cardiovascular biology.

Authors:  Cecilia C Low Wang; Marc L Goalstone; Boris Draznin
Journal:  Diabetes       Date:  2004-11       Impact factor: 9.461

6.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study.

Authors:  G S Tell; L P Fried; B Hermanson; T A Manolio; A B Newman; N O Borhani
Journal:  Ann Epidemiol       Date:  1993-07       Impact factor: 3.797

8.  Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group.

Authors:  A B Newman; D S Siscovick; T A Manolio; J Polak; L P Fried; N O Borhani; S K Wolfson
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

9.  Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study.

Authors:  Emelia J Benjamin; Martin G Larson; Michelle J Keyes; Gary F Mitchell; Ramachandran S Vasan; John F Keaney; Birgitta T Lehman; Shuxia Fan; Ewa Osypiuk; Joseph A Vita
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

Review 10.  Lipids and lipoproteins in patients with type 2 diabetes.

Authors:  Ronald M Krauss
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

View more
  16 in total

1.  Traditional and non-traditional risk factors for incident peripheral arterial disease among patients with chronic kidney disease.

Authors:  Jing Chen; Emile R Mohler; Dawei Xie; Michael Shlipak; Raymond R Townsend; Lawrence J Appel; Akinlolu Ojo; Martin Schreiber; Lisa Nessel; Xiaoming Zhang; Dominic Raj; Louise Strauss; Claudia M Lora; Mahboob Rahman; L Lee Hamm; Jiang He
Journal:  Nephrol Dial Transplant       Date:  2015-12-18       Impact factor: 5.992

Review 2.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

3.  Serum urate levels and the risk of hip fractures: data from the Cardiovascular Health Study.

Authors:  Tapan Mehta; Petra Bůžková; Mark J Sarnak; Michel Chonchol; Jane A Cauley; Erin Wallace; Howard A Fink; John Robbins; Diana Jalal
Journal:  Metabolism       Date:  2014-11-21       Impact factor: 8.694

4.  The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.

Authors:  K J Burghardt; R Pop-Busui; M J Bly; T B Grove; S F Taylor; V L Ellingrod
Journal:  Clin Transl Sci       Date:  2012-11-01       Impact factor: 4.689

5.  Endothelial Palmitoylation Cycling Coordinates Vessel Remodeling in Peripheral Artery Disease.

Authors:  Xiaochao Wei; Sangeeta Adak; Mohamed Zayed; Li Yin; Chu Feng; Sarah L Speck; Rahul S Kathayat; Qiang Zhang; Bryan C Dickinson; Clay F Semenkovich
Journal:  Circ Res       Date:  2020-04-01       Impact factor: 17.367

6.  Twenty-Year Predictors of Peripheral Arterial Disease Compared With Coronary Heart Disease in the Scottish Heart Health Extended Cohort (SHHEC).

Authors:  Hugh Tunstall-Pedoe; Sanne A E Peters; Mark Woodward; Allan D Struthers; Jill J F Belch
Journal:  J Am Heart Assoc       Date:  2017-09-18       Impact factor: 5.501

7.  Triglyceride-glucose index in the development of peripheral artery disease: findings from the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Jing-Wei Gao; Qing-Yun Hao; Ming Gao; Kun Zhang; Xiong-Zhi Li; Jing-Feng Wang; Dominique A Vuitton; Shao-Ling Zhang; Pin-Ming Liu
Journal:  Cardiovasc Diabetol       Date:  2021-06-24       Impact factor: 9.951

8.  Insulin resistance is significantly associated with the metabolic syndrome, but not with sonographically proven peripheral arterial disease.

Authors:  Alexander Vonbank; Christoph H Saely; Philipp Rein; Heinz Drexel
Journal:  Cardiovasc Diabetol       Date:  2013-07-17       Impact factor: 9.951

9.  Elevated Glucose Oxidation, Reduced Insulin Secretion, and a Fatty Heart May Be Protective Adaptions in Ischemic CAD.

Authors:  J C Hannukainen; R Lautamäki; A Mari; J P Pärkkä; M Bucci; M A Guzzardi; S Kajander; T Tuokkola; J Knuuti; P Iozzo
Journal:  J Clin Endocrinol Metab       Date:  2016-04-05       Impact factor: 5.958

Review 10.  Primary prevention of cardiovascular disease in older adults in China.

Authors:  Jian Yong; Dong Lin; Xue-Rui Tan
Journal:  World J Clin Cases       Date:  2017-09-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.